NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
Key Highlights
- ➤Preliminary Q3 revenue approximately $209 million
- ➤NGS revenue growth approximately 28% year over year
- ➤Full-year total revenue guidance expected to increase at midpoint
- ➤Warren Stone becomes CEO and board member January 4, 2027
- ➤Tony Zook becomes Executive Chairman January 4, 2027
Expert Statements
Tony Zook, CEO of NeoGenomics
“This leadership transition reflects years of deliberate succession planning by the Board and cements the continuity of our executive team and a consistent strategy for durable, profitable growth at NeoGenomics.”
Tony Zook, CEO of NeoGenomics
“Over the past several years, I have witnessed firsthand Warren’s ability to lead enterprise-wide functions and projects, which have advanced many of our key priorities, such as commercial expansion and customer impact, new product introductions, and our Lab of the Future initiatives.”
Tony Zook, CEO of NeoGenomics
“With our aligned long-term strategy in place and delivering results, this transition emphasizes strategic continuity.”
Tony Zook, CEO of NeoGenomics
“Warren and I will continue to work hand-in-hand to ensure his smooth transition to CEO and collaborate seamlessly thereafter as I assume the role of Executive Chair to ensure stability and execution against our objectives.”
Warren Stone, President and Chief Operating Officer of NeoGenomics
“Leading NeoGenomics is both a privilege and a responsibility that I have prepared for, and I am grateful for the Board's and Tony’s confidence.”
Warren Stone, President and Chief Operating Officer of NeoGenomics
“We are in the business of ensuring that every treatment decision is as personal as the patient, and that mission is exactly why the opportunity ahead of us is so compelling.”
Warren Stone, President and Chief Operating Officer of NeoGenomics
“Tony, the leadership team, and I have worked in close partnership to establish the strategy, the capabilities, and the foundation for our next chapter.”
Warren Stone, President and Chief Operating Officer of NeoGenomics
“I believe that NeoGenomics is exceptionally well positioned to lead the evolution of the oncology diagnostics market in delivering the outcomes that matter most to patients and the physicians who care for them, and I am excited to partner with the remarkable NeoGenomics team to deliver our full potential.”
Lynn Tetrault, Chair of the Board of Directors of NeoGenomics
“I am proud of what this organization has achieved since I joined the Board. Now, the Company is even better positioned for the future, and today’s announcements underscore the Board’s commitment to position NeoGenomics for long-term success.”
Lynn Tetrault, Chair of the Board of Directors of NeoGenomics
“I speak for the entire Board when I say Tony and Warren are best suited for these positions, with each bringing diverse and complementary skills and experiences.”
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
* Warren Stone, current President and COO, to become CEO and a member of the Board effective January 4, 2027 * Tony Zook to remain CEO through January 3, 2027, and become Executive Chairman effective January 4, 2027 * Lynn Tetrault, current Chair and Board member since 2015, to step down as Chair effective January 4, 2027, continue to serve as an independent director until the 2027 Annual Meeting of Stockholders, and not stand for reelection at that meeting * Michael Kelly to serve as Lead Independent Director effective January 4, 2027 * Preliminary unaudited third quarter revenue is expected to be approximately $209 million, with NGS revenue growth of approximately 28%. Full-year total revenue guidance expected to increase at midpoint, resulting from third-quarter performance NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer (COO), as Chief Executive Officer (CEO) and a member of the Board, effective January 4, 2027. Tony Zook, the Company’s current CEO and a member of the Board, will assume the role of Executive Chair at that time and will continue to work in close alignment with Mr. Stone and the Board.
Get started
Create a free account to read the full story.